Format

Send to

Choose Destination
Nutrients. 2018 Jun 9;10(6). pii: E750. doi: 10.3390/nu10060750.

A Double-Blind, Randomized Controlled, Acute Feeding Equivalence Trial of Small, Catalytic Doses of Fructose and Allulose on Postprandial Blood Glucose Metabolism in Healthy Participants: The Fructose and Allulose Catalytic Effects (FACE) Trial.

Braunstein CR1,2, Noronha JC3,4, Glenn AJ5,6, Viguiliouk E7,8, Noseworthy R9, Khan TA10,11, Au-Yeung F12,13, Blanco Mejia S14,15, Wolever TMS16,17,18,19,20, Josse RG21,22,23, Kendall CWC24,25,26, Sievenpiper JL27,28,29,30.

Author information

1
Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Risk Factor Modification Centre, Toronto, ON M5C 2T2, Canada. catherine.braunstein@mail.utoronto.ca.
2
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON M5S 3E2, Canada. catherine.braunstein@mail.utoronto.ca.
3
Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Risk Factor Modification Centre, Toronto, ON M5C 2T2, Canada. jarvis.noronha@mail.utoronto.ca.
4
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON M5S 3E2, Canada. jarvis.noronha@mail.utoronto.ca.
5
Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Risk Factor Modification Centre, Toronto, ON M5C 2T2, Canada. andrea.glenn@alum.utoronto.ca.
6
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON M5S 3E2, Canada. andrea.glenn@alum.utoronto.ca.
7
Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Risk Factor Modification Centre, Toronto, ON M5C 2T2, Canada. effie.viguiliouk@mail.utoronto.ca.
8
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON M5S 3E2, Canada. effie.viguiliouk@mail.utoronto.ca.
9
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON M5S 3E2, Canada. rebecca.noseworthy@utoronto.ca.
10
Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Risk Factor Modification Centre, Toronto, ON M5C 2T2, Canada. tauseef.khan@utoronto.ca.
11
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON M5S 3E2, Canada. tauseef.khan@utoronto.ca.
12
Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Risk Factor Modification Centre, Toronto, ON M5C 2T2, Canada. rodney.auyeung@mail.utoronto.ca.
13
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON M5S 3E2, Canada. rodney.auyeung@mail.utoronto.ca.
14
Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Risk Factor Modification Centre, Toronto, ON M5C 2T2, Canada. sonia.blancomejia@mail.utoronto.ca.
15
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON M5S 3E2, Canada. sonia.blancomejia@mail.utoronto.ca.
16
Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Risk Factor Modification Centre, Toronto, ON M5C 2T2, Canada. thomas.wolever@utoronto.ca.
17
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON M5S 3E2, Canada. thomas.wolever@utoronto.ca.
18
Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON M5S 3E2, Canada. thomas.wolever@utoronto.ca.
19
Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON M5B 1T8, Canada. thomas.wolever@utoronto.ca.
20
Division of Endocrinology and Metabolism, St. Michael's Hospital, Toronto, ON M5C 2T2, Canada. thomas.wolever@utoronto.ca.
21
Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Risk Factor Modification Centre, Toronto, ON M5C 2T2, Canada. josserg@smh.ca.
22
Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON M5B 1T8, Canada. josserg@smh.ca.
23
Division of Endocrinology and Metabolism, St. Michael's Hospital, Toronto, ON M5C 2T2, Canada. josserg@smh.ca.
24
Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Risk Factor Modification Centre, Toronto, ON M5C 2T2, Canada. cyril.kendall@utoronto.ca.
25
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON M5S 3E2, Canada. cyril.kendall@utoronto.ca.
26
College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK S7N 5C9, Canada. cyril.kendall@utoronto.ca.
27
Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Risk Factor Modification Centre, Toronto, ON M5C 2T2, Canada. john.sievenpiper@medportal.ca.
28
Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON M5S 3E2, Canada. john.sievenpiper@medportal.ca.
29
Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON M5B 1T8, Canada. john.sievenpiper@medportal.ca.
30
Division of Endocrinology and Metabolism, St. Michael's Hospital, Toronto, ON M5C 2T2, Canada. john.sievenpiper@medportal.ca.

Abstract

Recent literature suggests that catalytic doses (≤10 g/meal or 36 g/day) of D-fructose and D-allulose may reduce postprandial blood glucose responses to carbohydrate loads in people with and without type 2 diabetes by inducing glycogen synthesis. To assess the effect of small single doses of fructose and allulose on postprandial blood glucose regulation in response to a 75 g-oral glucose tolerance test (75 g-OGTT) in healthy individuals, we conducted an acute randomized, crossover, equivalence trial in healthy adults. Each participant randomly received six treatments, separated by a minimum one-week washout. Treatments consisted of a 75 g-OGTT with the addition of fructose or allulose at 0 g (control), 5 g or 10 g. A standard 75 g-OGTT protocol was followed with blood samples at −30, 0, 30, 60, 90, 120 min. The primary outcome was the difference in plasma glucose incremental area under the curve (iAUC). A total of 27 participants underwent randomization with data available from 25 participants. Small doses of fructose or allulose did not show a significant effect on plasma glucose iAUC or other secondary markers of postprandial blood glucose regulation in response to a 75 g-OGTT in healthy individuals. These results were limited by the low power to detect a significant difference, owing to greater than expected intra-individual coefficient of variation (CV) in plasma glucose iAUC. Overall, we failed to confirm the catalytic effects of small doses of fructose and allulose in healthy individuals. Future trials may consider recruiting larger sample sizes of healthy individuals.

TRIAL REGISTRATION:

clinicaltrials.gov identifier, NCT02459834.

KEYWORDS:

D-allulose; D-fructose; D-psicose; catalytic effects; postprandial blood glucose regulation

PMID:
29890724
PMCID:
PMC6024645
DOI:
10.3390/nu10060750
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center